|
2019 Conference Publication Value for money of putting precision into practice: Germline genetic testing to guide olaparib treatment in HER2-negative metastatic breast cancerTuffaha, Haitham and Scuffham, Paul (2019). Value for money of putting precision into practice: Germline genetic testing to guide olaparib treatment in HER2-negative metastatic breast cancer. COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, Adelaide, Australia, 12–14 November 2019. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.13262 |
|
2019 Conference Publication PCN349 Value of information analysis guiding the reimbursement decision of olaparib for metastatic breast cancerTuffaha, H. and Scuffham, P. (2019). PCN349 Value of information analysis guiding the reimbursement decision of olaparib for metastatic breast cancer. ISPOR Europe 2019, Copenhagen, Denmark, November 2019. New York, NY, United States: Elsevier. doi: 10.1016/j.jval.2019.09.544 |
|
2019 Conference Publication PCN95 cost-effectiveness analysis of germline BRCA mutation testing and olaparib treatment in metastatic breast cancer: an evaluation of codependent technologiesTuffaha, H. and Scuffham, P. (2019). PCN95 cost-effectiveness analysis of germline BRCA mutation testing and olaparib treatment in metastatic breast cancer: an evaluation of codependent technologies. ISPOR Europe 2019, Copenhagen, Denmark, 2-6 November 2019. New York, NY United States: Elsevier. doi: 10.1016/j.jval.2019.09.292 |
|
2019 Conference Publication Cost-effective analysis of supervised exercise training in men with prostate cancer previously treated with androgen deprivation therapy and radiationEdmunds, Kim, Reeves, Penny, Tuffaha, Haitham, Galvao, Daniel, Newton, Rob, Spry, Nigel, Denham, James, Taaffe, Dennis R., Joseph, David, Lamb, David S., Chambers, Suzanne K. and Scuffham, Paul (2019). Cost-effective analysis of supervised exercise training in men with prostate cancer previously treated with androgen deprivation therapy and radiation. COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, Adelaide, SA, Australia, 12–14 November 2019. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.13262 |
|
2018 Conference Publication Rare Cancers, no Rare Solutions: Risk Sharing Arrangemnts to Reimburse Medicines for Rare Cancers in AustraliaTuffaha, H. and Scuffham, P. (2018). Rare Cancers, no Rare Solutions: Risk Sharing Arrangemnts to Reimburse Medicines for Rare Cancers in Australia. Moving Into Action: Informing Policy and Strengthening Healthcare Systems in Asia-Pacific, Tokyo, Japan, 8-11 September 2018. Elsevier. doi: 10.1016/j.jval.2018.07.839 |
|
2018 Conference Publication Can we prospectively assess the value for money of oncology clinical trials?Tuffaha, Haitham, Chambers, Suzanne and Scuffham, Paul (2018). Can we prospectively assess the value for money of oncology clinical trials?. COSA's 45th Annual Scientific Meeting, Mesothelioma and Gastro‐Intestinal Cancers: Technology and Genomics, Perth, WA Australia, 13–15 November 2018. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.13089 |
|
2018 Conference Publication Can technology improve medication adherence in older people with dementia?El-Saifi, Najwan, Moyle, Wendy, Jones, Cindy and Tuffaha, Haitham (2018). Can technology improve medication adherence in older people with dementia?. 16th International Conference, ICOST 2018, Singapore, 10-12 July, 2018. Cham, Switzerland: Springer. doi: 10.1007/978-3-319-94523-1_1 |
|
2018 Conference Publication Value For Money, the Overlooked Aspect in Research Funding DecisionsTuffaha, H., El-Saifi, N. and Scuffham, P. (2018). Value For Money, the Overlooked Aspect in Research Funding Decisions. Moving Into Action: Informing Policy and Strengthening Healthcare Systems in Asia-Pacific, Tokyo, Japan, 8-11 September 2018. Elsevier. doi: 10.1016/j.jval.2018.07.413 |
|
2017 Conference Publication INTERNATIONAL HTA EXPERIENCE WITH TARGETED THERAPY APPROVALS FOR LUNG CANCERMaraiki, R., Bymes, J., Tuffaha, H. and Hider, M. (2017). INTERNATIONAL HTA EXPERIENCE WITH TARGETED THERAPY APPROVALS FOR LUNG CANCER. NEW YORK: ELSEVIER SCIENCE INC. |
|
2017 Conference Publication International HTA experience with targeted therapy approvals For lung cancerMaraiki, F., Byrnes, J., Tuffaha, H. and Hider, M. (2017). International HTA experience with targeted therapy approvals For lung cancer. ISPOR 20th Annual European Congress, Glasgow, United Kingdom, 4-8 November 2017. New York, NY USA: Elsevier. doi: 10.1016/j.jval.2017.08.335 |
|
2017 Conference Publication Improving patient access to novel cancer drugs in Australia: are we there yet?Tuffaha, Haitham and Scuffham, Paul (2017). Improving patient access to novel cancer drugs in Australia: are we there yet?. COSA's 44th Annual Scientific Meeting, Immunotherapy: Molecules and Mountains, Sydney, NSW Australia, 13-15 November 2017. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. |
|
2015 Conference Publication Health economic modelling for treatments and services in prostate cancer care: a master model for AustraliaGordon, Louisa, Tuffaha, Haitham, Scuffham, Paul and Lowe, Anthony (2015). Health economic modelling for treatments and services in prostate cancer care: a master model for Australia. 2nd Prostate Cancer World Congress (PCWC), Cairns, QLD, Australia, 17-21 August, 2015. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/bju.13196 |
|
2014 Conference Publication COST-EFFECTIVENESS AND VALUE OF INFORMATION ANALYSES OF NUTRITIONAL SUPPORT IN PREVENTING PRESSURE ULCERS IN HIGH RISK HOSPITALISED PATIENTSTuffaha, H. W., Shelley, R., Chaboyer, W., Gordon, L. G. and Scuffham, P. A. (2014). COST-EFFECTIVENESS AND VALUE OF INFORMATION ANALYSES OF NUTRITIONAL SUPPORT IN PREVENTING PRESSURE ULCERS IN HIGH RISK HOSPITALISED PATIENTS. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jval.2014.08.2150 |
|
2012 Conference Publication COMPARATIVE COST UTILITY ANALYSIS OF PLERIXAFOR PLUS GCSF VERSUS CYCLOPHOSPHAMIDE PLUS GCSF AS SALVAGE MOBILIZATION REGIMENS IN MULTIPLE MYELOMA PATIENTSTuffaha, H. W., Hussein, A. A. and Abdel-Rahman, F. A. (2012). COMPARATIVE COST UTILITY ANALYSIS OF PLERIXAFOR PLUS GCSF VERSUS CYCLOPHOSPHAMIDE PLUS GCSF AS SALVAGE MOBILIZATION REGIMENS IN MULTIPLE MYELOMA PATIENTS. BMT Tandem Meeting, San Diego Ca, Feb 01-05, 2012. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.bbmt.2011.12.132 |
|
2012 Conference Publication THE EFFECTIVENESS AND COST EFFECTIVENESS OF PLERIXAFOR plus GCSF VERSUS GCSF +/- CHEMOTHERAPY AS SALVAGE MOBILIZATION REGIMENS IN LYMPHOMA AND MULTIPLE MYELOMA PATIENTSTuffaha, H. W., Hussein, A. A., Sharma, S., Abu-Jazar, H., Al-Rawi, O. S., Saad, A. M., Al-Zaben, A., Hussein, N. and Abdel-Rahman, F. A. (2012). THE EFFECTIVENESS AND COST EFFECTIVENESS OF PLERIXAFOR plus GCSF VERSUS GCSF +/- CHEMOTHERAPY AS SALVAGE MOBILIZATION REGIMENS IN LYMPHOMA AND MULTIPLE MYELOMA PATIENTS. BMT Tandem Meeting, San Diego Ca, Feb 01-05, 2012. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.bbmt.2011.12.130 |
|
2012 Conference Publication Adverse drug reactions in bone marrow transplant patientsNajjar, R., Tuffaha, H., Abdel-Rahman, F., Hussein, A. and Jazar, H. A. (2012). Adverse drug reactions in bone marrow transplant patients. 38th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT), Geneva, Switzerland, 1-4 April, 2012. London, United Kingdom: Nature Publishing Group. doi: 10.1038/bmt.2012.37 |
